ArticleBMC cancer2025
The value of translational therapy in the treatment of advanced hepatoid adenocarcinoma of stomach.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundAdvanced hepatoid adenocarcinoma of stomach still lacks effective and standardized treatment options. This study aims to explore the therapeutic value of translational therapy in advanced hepatoid adenocarcinoma of stomach.
methodsWe conducted a retrospective analysis of 37 patients with advanced hepatoid adenocarcinoma of stomach who successfully underwent translational therapy followed by surgical intervention between October 2009 and October 2024. Through survival analysis and Cox regression, we identified the clinicopathological factors that significantly impact patient prognosis.
resultsThe median survival time of 37 patients was 39.0 months. 70.3% of patients achieved R0 resection, with an average OS 93.8 months and a 5-year survival rate of 64.4%. And 10.8% of patients achieved pathological complete remission, with an average OS of 65.7 months and a 5-year survival rate of 100%. Additionally, radical surgery, pM stage, cytology, and surgery type were identified as independent risk factors influencing the prognosis of patients.
conclusionTranslational therapy is a promising strategy for patients with initially unresectable advanced hepatoid adenocarcinoma of stomach. Achieving R0 resection and attaining pathological complete remission are crucial milestones in improving patient prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.